Stromal-targeting radioimmunotherapy mitigates the progression of therapy-resistant tumors.
Bolli E, D'Huyvetter M, Murgaski A, Berus D, Stangé G, Clappaert EJ, Arnouk S, Pombo Antunes AR, Krasniqi A, Lahoutte T, Gonçalves A, Vuylsteke M, Raes G, Devoogdt N, Movahedi K, Van Ginderachter JA.
Bolli E, et al.
J Control Release. 2019 Nov 28;314:1-11. doi: 10.1016/j.jconrel.2019.10.024. Epub 2019 Oct 15.
J Control Release. 2019.
PMID: 31626860